| JPMORGAN ELECT PLC (the 'Company') |
|
| Legal Entity Identifier: 549300FIUYKKL39ILD07 | |
| THE COMPANY ANNOUNCES THE TEN LARGEST INVESTMENTS IN % OF TOTAL ASSETS As at: 31 October 2022 | |
| Managed Growth portfolio |
|
| JPMorgan American Inv Trust | 14.8% |
| JPMorgan Claverhouse Inv Trust | 8.2% |
| JPM UK Equity Plus C | 7.9% |
| Finsbury Growth & Income | 7.4% |
| JPMorgan UK Dynamic C | 6.9% |
| JPMorgan US Equity All Capital C | 6.3% |
| JPMorgan US Value Fund | 4.1% |
| Murray Income Trust | 3.6% |
| JPMorgan US Select Equity C | 3.5% |
| Fidelity | 3.3% |
| Total | 66.0% |
| Excludes Investments in Liquidity stocks | |
| Managed Income portfolio |
|
| Shell | 9.0% |
| AstraZeneca | 7.7% |
| BP | 6.2% |
| Glencore | 4.0% |
| British American Tobacco | 4.0% |
| Barclays | 3.1% |
| GSK | 3.1% |
| BAE Systems Plc | 2.6% |
| OSB | 2.6% |
| Unilever | 2.4% |
| Total | 44.6% |
| Excludes Investments in Liquidity stocks | |
| * Based on invested portfolio | |
| Name of contact and telephone number for queries: | |
| Paul Ainger 0044 207 742 6524 | |
| Name of authorised company official responsible for making this notification: | |
| Priyanka Vijay Anand 0044 203 493 1504 - Company Secretary | |
| Date: 14 November 2022 | |
| | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.